WILMINGTON, DE \u2014 Novartis has agreed to acquire Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, in a deal valued at up to $3 billion to expand its oncology pipeline, the companies announced.<\/p>\n
The agreement includes $2 billion in upfront cash and up to $1 billion in development, regulatory, and commercial milestone payments.<\/p>\n
Pikavation\u2019s portfolio includes SNV4818, a PI3K\u03b1 inhibitor currently in Phase 1\/2 clinical trials for HR-positive, HER2-negative metastatic breast cancer and other solid tumors.<\/p>\n
Under the terms of the deal, Novartis will assume responsibility for the development and commercialization of SNV4818 and related programs.<\/p>\n
The transaction is expected to close in the first half of 2026, pending regulatory review, including clearance under U.S. antitrust laws.<\/p>\n
Synnovation will retain ownership of its remaining research and development subsidiaries and continue advancing its pipeline, including SNV1521, a PARP1 inhibitor currently in Phase 1 trials.<\/p>\n
Wenqing Yao, Synnovation\u2019s chief executive officer, said the agreement is expected to accelerate development of SNV4818 for patients with PI3K\u03b1 mutation-driven tumors.<\/p>\n
Centerview Partners is serving as financial advisor to Synnovation, with Goodwin Procter LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acting as legal advisors.<\/p>\n
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News<\/a> and MSN<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"WILMINGTON, DE \u2014 Novartis has agreed to acquire Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, in a deal…\n","protected":false},"author":2,"featured_media":15232,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[1766,206,25680],"class_list":["post-44545","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-acquisitions","tag-novartis","tag-wilmington-business-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116351258057081102","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=44545"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44545\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/15232"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=44545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=44545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=44545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}